Atria Investments Inc lessened its position in shares of Chemed Co. (NYSE:CHE - Free Report) by 13.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,122 shares of the company's stock after selling 666 shares during the quarter. Atria Investments Inc's holdings in Chemed were worth $2,184,000 at the end of the most recent quarter.
Several other large investors have also made changes to their positions in the company. Farther Finance Advisors LLC boosted its stake in Chemed by 2,314.3% in the third quarter. Farther Finance Advisors LLC now owns 338 shares of the company's stock valued at $203,000 after acquiring an additional 324 shares during the last quarter. QRG Capital Management Inc. grew its stake in shares of Chemed by 5.1% during the third quarter. QRG Capital Management Inc. now owns 1,368 shares of the company's stock worth $822,000 after purchasing an additional 66 shares during the period. Impax Asset Management Group plc increased its holdings in Chemed by 4.7% in the third quarter. Impax Asset Management Group plc now owns 332,757 shares of the company's stock valued at $199,977,000 after purchasing an additional 14,814 shares during the last quarter. Legacy Capital Wealth Partners LLC lifted its stake in Chemed by 87.8% in the third quarter. Legacy Capital Wealth Partners LLC now owns 1,979 shares of the company's stock valued at $1,189,000 after buying an additional 925 shares during the period. Finally, TimesSquare Capital Management LLC boosted its holdings in Chemed by 7.5% during the third quarter. TimesSquare Capital Management LLC now owns 167,135 shares of the company's stock worth $100,443,000 after buying an additional 11,595 shares during the last quarter. Institutional investors and hedge funds own 95.85% of the company's stock.
Chemed Stock Performance
NYSE CHE traded up $0.79 during trading hours on Thursday, reaching $590.03. 69,255 shares of the company's stock were exchanged, compared to its average volume of 100,863. The company has a market capitalization of $8.64 billion, a price-to-earnings ratio of 29.81, a price-to-earnings-growth ratio of 2.15 and a beta of 0.43. The company's 50-day moving average is $557.78 and its two-hundred day moving average is $564.44. Chemed Co. has a one year low of $512.12 and a one year high of $654.62.
Chemed Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 14th. Investors of record on Monday, February 24th will be given a $0.50 dividend. The ex-dividend date of this dividend is Monday, February 24th. This represents a $2.00 annualized dividend and a yield of 0.34%. Chemed's dividend payout ratio is currently 10.05%.
Wall Street Analyst Weigh In
Separately, StockNews.com raised shares of Chemed from a "hold" rating to a "buy" rating in a research note on Friday, March 7th.
Read Our Latest Analysis on Chemed
Insider Buying and Selling
In related news, CEO Kevin J. Mcnamara sold 2,000 shares of Chemed stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $593.67, for a total value of $1,187,340.00. Following the sale, the chief executive officer now owns 102,679 shares of the company's stock, valued at approximately $60,957,441.93. This trade represents a 1.91 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Brian C. Judkins purchased 145 shares of Chemed stock in a transaction on Monday, December 30th. The shares were purchased at an average cost of $519.50 per share, with a total value of $75,327.50. Following the transaction, the vice president now owns 1,678 shares in the company, valued at approximately $871,721. The trade was a 9.46 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 3.32% of the company's stock.
Chemed Company Profile
(
Free Report)
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
Further Reading
Before you consider Chemed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemed wasn't on the list.
While Chemed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
